Chinese health care authorities declined to include Pfizer’s covid19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.
News Today | First with the news
News Today | First with the news
Chinese health care authorities declined to include Pfizer’s covid19 treatment drug in a national reimbursement list that would have allowed patients to get it at a cheaper price throughout the country, saying it was too expensive.